利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.025 秒)

    METHODS FOR TREATING PAIN INDUCED BY INJURIES AND DISEASES OF AN ARTICULAR JOINT
    1.
    发明申请
    METHODS FOR TREATING PAIN INDUCED BY INJURIES AND DISEASES OF AN ARTICULAR JOINT 审中-公开
    用于治疗由伤口引起的疼痛和关节联合疾病的方法

    公开(公告)号：US20110224138A1

    公开(公告)日：2011-09-15

    申请号：US12878716

    申请日：2010-09-09

    申请人： Julie Krop ,  Marilyn Pike ,  Dean Falb ,  Bret Shirley ,  Denis Schrier ,  Mary Elizabeth Goad

    发明人： Julie Krop ,  Marilyn Pike ,  Dean Falb ,  Bret Shirley ,  Denis Schrier ,  Mary Elizabeth Goad

    IPC分类号： A61K38/18 ,  A61P29/00 ,  A61P19/08

    CPC分类号： A61K38/1875

    摘要： Described herein are methods for using bone morphogenetic proteins (BMPs), such as OP-1 (also known as BMP-7), to treat pain caused by osteoarthritis. The methods involve administering to a patient suffering from pain caused by osteoarthritis a BMP, for example, intraarticularly by injection directly into the joint afflicted with osteoarthritis. The methods of the invention provide long-term pain relief to sufferers of osteoarthritis and can improve the functionality of the joint to which the BMP is administered.

    摘要翻译： 本文描述了使用骨形态发生蛋白（BMP）如OP-1（也称为BMP-7）来治疗由骨关节炎引起的疼痛的方法。 所述方法包括向患有由骨关节炎引起的疼痛的患者施用BMP，例如通过注射直接注射到患有骨关节炎的关节中。 本发明的方法为骨关节炎患者提供长期的疼痛缓解，并且可以改善施用BMP的关节的功能。

    INJECTABLE FORMULATIONS CONTAINING SUCCINATE
    3.
    发明申请
    INJECTABLE FORMULATIONS CONTAINING SUCCINATE 审中-公开
    含有成分的注射剂

    公开(公告)号：US20070249522A1

    公开(公告)日：2007-10-25

    申请号：US11773184

    申请日：2007-07-03

    申请人： Bret Shirley ,  Maninder Hora

    发明人： Bret Shirley ,  Maninder Hora

    IPC分类号： A61K38/30 ,  A61K31/21

    CPC分类号： A61K9/0019 ,  A61K38/30 ,  A61K47/12

    摘要： The invention is directed to formulations of a pharmaceutically active agent for in vivo use. The formulations to which the invention is directed are designed to minimize the pain associated with components in injectable formulations, other than the pharmaceutically active agent. The invention is particularly directed to buffers that provide for minimum pain upon injection. Insulin-like growth factor I (IGF-I) is a preferred pharmaceutically active agent.

    摘要翻译： 本发明涉及用于体内使用的药物活性剂的制剂。 本发明所针对的制剂被设计成尽可能减少与可注射制剂中除药学活性剂之外的组分相关的疼痛。 本发明特别涉及提供注射时最小疼痛的缓冲液。 胰岛素样生长因子I（IGF-I）是优选的药物活性剂。

    High and low load formulations of IGF-I in multivesicular liposomes
    5.
    发明授权
    High and low load formulations of IGF-I in multivesicular liposomes 失效
    IGF-I在多泡脂质体中的高负荷和低负荷配方

    公开(公告)号：US06306432B1

    公开(公告)日：2001-10-23

    申请号：US08925531

    申请日：1997-09-08

    申请人： Bret Shirley ,  Maninder Hora ,  Qiang Ye ,  Nandini Katre ,  John Asherman

    发明人： Bret Shirley ,  Maninder Hora ,  Qiang Ye ,  Nandini Katre ,  John Asherman

    IPC分类号： A61K9127

    CPC分类号： A61K9/1277 ,  A61K38/30

    摘要： Disclosed are multivesicular liposomes (MVLs) containing IGF-I with substantially full bioavailability, wherein the loading of the IGF-I into the liposomes is modulated by adjusting the osmolarity of the aqueous component into which the agents are dissolved prior to encapsulation. In the making of MVLs, the process involves dissolving the IGF-I, an osmolarity excipient, and a pH modifying agent sufficient to solubilize the IGF-I in a first aqueous component used during manufacture of the MVLs. To increase the loading of the IGF-I, the osmolarity of the aqueous component used during manufacture of the MVLs is reduced, whereas the osmolarity of the aqueous component is increased to obtain the low load formulations. The rate of release of the active agent into the surrounding environment in which the liposomes are introduced can be simultaneously controlled by incorporating into the lipid component used in the formulation at least one long chain amphipathic lipid. Use of the long chain amphipathic lipid in the lipid component is particularly helpful in controlling the release rate from high drug load formulations.

    摘要翻译： 公开了含有基本上具有完全生物利用度的IGF-I的多泡脂质体（MVL），其中通过在包封之前调节其中溶解有药剂的水性组分的渗透压，调节IGF-1进入脂质体的载体。 在制备MVL时，该方法包括将制备所述MVL的第一水性成分中的IGF-I，渗透性赋形剂和pH调节剂溶解在足以溶解IGF-I的第一水溶性成分中。 为了增加IGF-I的负载量，在制造MVL期间使用的水性组分的渗透压降低，而水性组分的渗透压增加以获得低负荷制剂。 引入脂质体的周围环境中活性剂的释放速率可以通过将至少一种长链两亲性脂质掺入用于制剂中的脂质组分中来同时控制。 在脂质组分中使用长链两亲脂质特别有助于控制高药物负荷制剂的释放速率。

    Novel IGF-1 composition and its use
    6.
    发明申请
    Novel IGF-1 composition and its use 失效
    新型IGF-1组合物及其用途

    公开(公告)号：US20050266046A1

    公开(公告)日：2005-12-01

    申请号：US11195008

    申请日：2005-08-02

    申请人： Bret Shirley ,  Maninder Hora

    发明人： Bret Shirley ,  Maninder Hora

    IPC分类号： A61K9/00 ,  A61K9/16 ,  A61K38/30 ,  A61K9/22

    CPC分类号： A61K38/30 ,  A61K9/0024 ,  A61K9/1647 ,  A61K9/1694

    摘要： A highly concentrated, low salt-containing, biologically active syrup form of IGF-I or variant thereof and methods for its preparation are provided. This novel syrup form of IGF-I has an IGF-I concentration of at least about 250 mg/ml, a density of about 1.0 g/ml to about 1.2 g/ml, and a viscosity of about 13,000 centipoise (cps) to about 19,000 cps, as measured at ambient temperature (23° C.). The IGF-I syrup is prepared by precipitating or partitioning IGF-I from solution, preferably by adjusting the solution pH or by use of a solubility enhancer to concentrate IGF-I in solution followed by removal of the solubility enhancer. The precipitated syrup is useful as a means of storing IGF-I in a stable form and as a means of preparing compositions comprising biologically active IGF-I. Pharmaceutical compositions and kits comprising this concentrated IGF-I syrup are provided. The precipitated IGF-I syrup, IGF-I reconstituted from the IGF-I syrup, pharmaceutical compositions, and kits are useful in IGF-I therapy directed to IGF-I-responsive conditions.

    摘要翻译： 提供了高浓度，低含盐，生物活性糖浆形式的IGF-I或其变体及其制备方法。 IGF-I的这种新型糖浆形式具有至少约250mg / ml的IGF-I浓度，约1.0g / ml至约1.2g / ml的密度，约13,000厘泊（cps）至约 在环境温度（23℃）下测量的19,000cps。 IGF-I糖浆通过从溶液中沉淀或分配IGF-I来制备，优选通过调节溶液pH或通过使用溶解度增强剂将IGF-I浓缩在溶液中，然后除去溶解度增强剂。 沉淀的糖浆可用作以稳定形式存储IGF-I的手段，并且作为制备包含生物活性IGF-I的组合物的手段。 提供了包含该浓缩的IGF-1糖浆的药物组合物和试剂盒。 从IGF-I糖浆重建的沉淀的IGF-1糖浆，IGF-I，药物组合物和试剂盒可用于针对IGF-1反应性条件的IGF-1治疗。